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Abstract: Image-guided stereotactic ablative radiotherapy (SABR; 
also called stereotactic body radiotherapy or radiosurgery) has 
become a standard treatment for medically inoperable peripherally 
located stage I non–small-cell lung cancer (NSCLC) and can achieve 
local control rates in excess of 90%. However, the role of SABR for 
centrally located lesions remains controversial because of concerns 
about the potential for severe toxic effects. When cutting-edge tech-
nologies and knowledge-based optimization of SABR planning that 
considers both target coverage and normal tissue sparing are used, 
some patients with central lesions can be safely and effectively cured 
of early stage NSCLC. However, delivery of ablative doses of radia-
tion to critical structures such as bronchial tree, esophagus, major 
vessels, heart, and the brachial plexus/phrenic nerve could produce 
severe, potentially lethal toxic effects. Here, we address the current 
understanding of indications, dose regimens, planning optimization, 
and normal tissue dose-volume constraints for using SABR to treat 
central NSCLC.
Key Words: SABR, SBRT, Central lesion, Early stage lung cancer, 
Dose-volume constraints, Toxicity, Survival.
(J Thorac Oncol. 2015;10: 577–585)
Image-guided stereotactic ablative radiotherapy (SABR; also called stereotactic body radiotherapy) delivers focused, abla-
tive radiation doses to a target while minimizing the dose to 
surrounding critical normal structures. It has produced local 
control rates in excess of 90% for patients with early stage 
non–small-cell lung cancer (NSCLC) when the biological 
effective dose (BED) to the planning target volume (PTV) is 
greater than 100 Gy.1–4 Population-based studies and propen-
sity-matched analyses demonstrate that SABR produces over-
all survival (OS) and disease-specific survival rates similar to 
those after lobectomy, and better OS than conventional radia-
tion.5–7 Currently, SABR is replacing conventional radiother-
apy for the treatment of patients with medically inoperable, 
peripherally located stage I lung cancer1–7 or multiple-primary 
early stage NSCLC.8 The role of SABR in oligometastatic 
disease9,10 or recurrent disease in the lung parenchyma11 is 
being investigated, and clinical findings have been promis-
ing. However, the use of SABR for lesions that are centrally 
located and thus close to critical normal structures within the 
thorax is controversial.12–18 A low rate of freedom from grade 
3‒5 toxicity (54% at 2 years) in one study in which 60–66 
Gy in three fractions was used12 and reports of severe toxicity 
including fatal hemoptysis, pneumonitis, and fistula14,15 have 
discouraged many from using this technique. However, other 
SABR regimens such as 48–50 Gy in four to five fractions,13,17 
60 Gy in eight fractions,16,18 and 50–70 Gy in 10 fractions19 
have been shown to be safe and well tolerated in carefully 
selected patients. Whether SABR should be considered for 
central lesions only in the context of clinical protocols con-
tinues to be debated because of uncertainty about potential 
severe adverse effects. Recently, however, findings from sev-
eral large clinical series reporting long-term clinical outcomes 
after SABR for central lesions support the use of this tech-
nique for curative treatment of centrally located early stage 
NSCLC, and the authors of these studies have proposed dose-
volume constraints for some regimens based on their clinical 
experience.20–23 Notably, however, low BEDs (less than 100 
Gy) resulted in higher rates of local failure, whereas higher 
ablative doses to critical structures can cause severe or even 
fatal toxicity. Thus, maintaining balance between adequate 
target coverage and minimizing doses exposure to critical 
structures remains crucial.
Unfortunately, published findings are quite inconsis-
tent regarding what constitutes a central lesion, indications 
for SABR, SABR regimens, techniques, dose prescription 
methods, calculation algorithms, image guidance, and defi-
nition of local failure after SABR. Proper selection of cases, 
based on tumor location and the ability to meet normal tis-
sue constraints, the careful choice of SABR regimens and 
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techniques, and the use of image guidance are all crucial for 
adequate target coverage while avoiding overdoses to critical 
structures. In this article, we review the existing literature 
and provide guidelines for the use of SABR for challeng-
ing cases. These guidelines can be used not only for early 
stage central lesions but also for oligometastastic central 
lesions, another emerging clinical practice currently under 
investigation.
DEFINITION OF “CENTRAL” AND INDICATIONS 
FOR SABR
The definition of what constitutes a “central lesion” has 
varied in published studies, and includes (1) a tumor within 
2 cm in all directions of the proximal bronchial tree (carina, 
right and left main bronchi, and bronchial tree to the second 
bifurcation), as in RTOG 0236; (2) a tumor within 2 cm in all 
directions of any mediastinal critical structure, including the 
bronchial tree, esophagus, heart, brachial plexus, major ves-
sels, spinal cord, phrenic nerve, and recurrent laryngeal nerve 
(Fig. 1); and (3) a tumor within 2 cm in all directions around 
the proximal bronchial tree and immediately adjacent to medi-
astinal or pericardial pleura (“PTV touching the mediastinal 
pleura”) as in RTOG 0813 (a phase I dose-escalation study of 
SABR for central lesions). Definition 2 has been used most 
often in recent studies because of reported toxicity to lung and 
other critical structures such as esophagus, heart, and nerves 
etc. after SABR. Therefore, we recommend the definition 2 
(Fig. 1) in our routing clinical practice. However, critical nor-
mal tissues should be respected when SABR is considered for 
central lesions. Tumors located at or involving the hilar struc-
tures, or tumors invading the bronchial tree or mediastinum, 
although physically “central,” are not considered safe targets 
for central SABR regimens, e.g., those involving delivery of 
a BED greater than 100 Gy in five or even up to 10 fractions. 
Treatment involving additional fractions should be considered 
for such lesions.
DOSE REGIMENS, TOXIC EFFECTS, 
AND NORMAL TISSUE DOSE-VOLUME 
CONSTRAINTS
The proximal bronchial tree was long considered a “no 
fly zone” for high-dose radiation, meaning 60 Gy in three frac-
tions (54 Gy in three fractions with heterogeneity correction, 
BED α/β
10
 = 151 Gy, BED α/β
3
 = 378 Gy), since early results 
of a phase II trial published in 2006 indicated that patients 
with tumors within a 2 cm radius of the trachea and bron-
chial tree were 11 times more likely to experience grade 3–5 
lung toxicity than were those with tumors outside this zone.12 
Indeed, a 4-year update of that study revealed lung toxicity 
rates of 27.3% for patients with central tumors versus 10.4% 
for those with peripheral tumors.24 Others also reported severe 
adverse effects such as bronchial stenosis, fatal hemoptysis, or 
fistula after SABR for central tumors when ablative dose were 
delivered to critical structures.14,15 To clarify the tolerance of 
critical structures, the RTOG conducted a phase I prospective 
study (RTOG 0813) to evaluate the toxicity of SABR in doses 
escalated from 50 Gy to 60 Gy, in five fractions delivered 
every other day (except over weekends), with at least 40 hours 
between treatments; when this review was written, the results 
of this study were still pending.
Since 2006, other SABR regimens have been reported 
for central lesions. Xia et al. reported using 70 Gy prescribed 
to the gross tumor volume (GTV) in 10 fractions (BED 
α/β
10
 = 119 Gy, BED α/β
3
 = 233 Gy) and achieved a local con-
trol rate of 93% at 3 years.19 No grade 3 or higher toxicity was 
reported for either central or peripheral lesions. These find-
ings support reconsideration of the use of SABR for centrally 
located tumors—when appropriate dose-volume constraints 
for normal tissues are used. Investigators at MD Anderson 
FIGURE 1.  Recommended defini-
tion of central lesion: a tumor within 
2 cm in all directions of any medias-
tinal critical structure, including the 
bronchial tree, esophagus, heart, 
brachial plexus, major vessels, spinal 
cord, phrenic nerve, and recurrent 
laryngeal nerve.
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reported a preliminary version of such constraints for cen-
tral lesions in 2008, along with outcomes after modern four-
dimensional computed tomography-based SABR planning 
and on-board volumetric image verification for a regimen 
involving delivery of 40–50 Gy in four fractions on consecu-
tive days.13 When 50 Gy was delivered (BED α/β
10
 = 112.5 
Gy, BED α/β
3
 = 258 Gy), the local control rate at 2 years was 
100% and no incidents of fatal toxicity were noted. In con-
trast, 40 Gy in four fractions was associated with poor local 
control (57%) and therefore was subsequently abandoned. 
Moreover, one patient who had received 40 Gy to the bra-
chial plexus experienced severe brachial plexus neuropathy. 
At that time, preliminary dose-volume constraints were pro-
posed and the protocol was amended to allow compromise 
of PTV coverage if needed to spare critical structures. An 
updated report from MD Anderson in 2014 describing the use 
of SABR with 50 Gy in four fractions for 100 patients with 
tumors near the bronchial tree or other critical mediastinal 
structures and brachial plexus showed that median survival 
time (58 months) and local control rates (96% at 2 years) were 
comparable to those for peripheral lesions treated with SABR 
to 50 Gy in four fractions.20 The incidence and severity of 
radiation pneumonitis and chest wall pain were also similar; 
no patient experienced grade 4 or 5 toxicity. The previously 
proposed dose-volume constraints for each critical structure 
for a regimen of 50 Gy in four fractions were analyzed and 
modified based on the findings from the expanded cohort; 
these dose-volume constraints are shown in Table 1. By way 
of comparison, the constraints for the brachial plexus, bron-
chial tree, major vessels, esophagus were lower than in the 
previous report, and constraints for chest wall and heart were 
added. Patients in whom these dose-volume constraints could 
not be met were treated with 70 Gy in 10 fractions, which led 
to similar local control with tolerable toxicity.21 This 70 of 10 
fractionation reduced late chest wall and brachial plexus tox-
icity, but it was not clear if it also minimized acute radiation 
pneumonitis and esophagitis. Moreover, a patient with tumor 
invading the hilum treated with 70 Gy (hilar D
max
 = 83 Gy) 
had fatal hemoptysis, which led to the recommendation that 
tumors that actually invade central structures should not be 
treated with high-BED schedules.
In Europe, Lagerwaard et al.1 also proposed adaptive 
dose regimens based on tumor location and reported promis-
ing outcomes in 2008. That group subsequently reported their 
results from using 60 Gy in eight fractions (BED α/β
10
 = 105 
Gy, BED α/β
3
 = 210 Gy) for 63 patients with central lesions; 
at 3 years, the local control rate was 93% and no grade 4 or 
5 toxicity had occurred and no dose volume-constraints were 
provided/proposed.16 A group at Memorial Sloan Kettering 
also reported their use of SABR based on intensity-mod-
ulated radiation therapy (IMRT) for 108 patients, most of 
whom received 45 Gy in five fractions (α/β
10
 = 85.5 Gy, BED 
α/β
3
 = 180 Gy); the local control rate at 2 years was 79%.22 
However, severe esophageal toxicity, including fistula in a 
patient with an esophageal D
max
 of 46 Gy, was reported and 
6 of 12 patients for whom the median esophageal D
max
 was 
30 Gy developed grade greater than or equal to two esopha-
gitis when the PTV overlapped the esophagus. Two patients 
developed fatal hemoptysis, one with tumor involving the 
hilum and a maximum dose to the right bronchial tree of 47 
Gy in five fractions, and the other with tumor encasing the left 
superior segmental bronchus with a maximum bronchial tree 
dose of 48 Gy in five fractions. Another group at the Cleveland 
Clinic similarly reported a case of esophageal fistula when 
the esophageal point dose exceeded 51 Gy and the V
48
 was 
>1 cm3.25 Investigators at the William Beaumont Hospital 
compared clinical outcomes for 125 patients after regimens 
that varied from 48 to 60 Gy in four to five fractions (BED 
α/β
10
 = 100–132 Gy, BED α/β
3
 = 240–300 Gy) for central 
versus peripheral lesions using propensity-matched analysis.23 
No significant differences were found in OS or severe toxicity. 
However, in other reports, a similar dose (40–60 Gy in five 
fractions) led to fatal hemoptysis when a D
max
 of greater than 
50 Gy was delivered to the pulmonary artery and bronchus.26,27
Local control of lung tumors seems to require a BED 
of no less than 100 Gy (calculated with the linear quadratic 
model).13,22,28 However, doses with BED exceeding 100 Gy 
represent a “double-edged sword” in terms of balancing tumor 
control with normal tissue damage. Therefore, it is crucial to 
balance coverage of the gross tumor to a BED greater than 
100 Gy with dose constraints to avoid damage to nearby criti-
cal structures.
Based on these findings from several large series, regi-
mens of 45–50 Gy in four fractions or 50–60 Gy in five frac-
tions can be considered for centrally located lesions if normal 
tissue dose-volume constraints can be met; alternatively, 60 
Gy in eight fractions or 70 Gy in 10 fractions can also be con-
sidered, particularly for patients for whom dose-volume con-
straints cannot be met using less than or equal to five fractions. 
More fractionated SABR regimens, such as 70 Gy in 10 frac-
tions, may be preferred to avoid chronic toxicity such as chest 
wall pain and brachial plexus neuropathy. Even when 8–10 
fractions are used, SABR may not be appropriate for tumors 
invading critical structures such as the esophagus, hilum, 
major vessels, main bronchus, heart, or brachial plexus. 
SABR also should not be used for lesions abutting or invading 
the phrenic, vagus, or recurrent laryngeal nerves.29 Normal 
tissue dose-volume constraints will depend on the dose regi-
mens used. Published dose-volume constraints for regimens 
of 50 Gy in four fractions, 70 Gy in 10 fractions, are shown 
in Table 1. For 50–60 Gy in five fractions, RTOG 0813 trail is 
ongoing and the dose-volume constraints are listed in Table 1 
but it still needs clinical data from RTOG 0813 to validate its 
safety. These guidelines can be used to guide clinical practice 
for specific dose regimens, and further modifications should 
be considered when more clinical data particularly prospec-
tive studies become available.
Notably, severe side effects could continue to appear 
1 to 2 years after treatment, and caution must be used when 
deeming a regimen safe if the median follow-up time is less 
than 2 years. Although the clinical reports reviewed in the pre-
ceding section suggest that most patients with central lesions 
can be treated safely with SABR as long as prudent planning 
principles are respected, it should be kept in mind that SABR 
toxicity could be higher than is currently recognized because 
of competing risks of death in these patients. Furthermore, 
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attributing clinical symptoms to SABR toxicity as opposed to 
the natural progress of comorbid conditions can be extremely 
difficult. Finally, particular caution should be used with regard 
to additional insults to already damaged normal tissues, such 
as biopsy, to prevent severe or even fatal complications.
DOSE PRESCRIPTION AND TREATMENT-
PLANNING OPTIMIZATION
Local tumor control after SABR seems to depend on 
the dose delivered to the PTV, and a BED greater than 100 
Gy seems to be required to achieve optimal local control. 
However, even when the prescribed dose is the same, the 
actual dose delivered to the PTV can vary drastically depend-
ing on where (to which isodose line or point) the dose was 
prescribed. For example, a dose of 50 Gy prescribed to the 
60% isodose line could deliver a maximum dose of 96 Gy 
to the PTV, with a total mean PTV dose of 83 Gy; in con-
trast, a dose of 50 Gy prescribed to the 100% isodose line 
could deliver only 32 Gy to some of the PTV, with a total 
mean PTV dose of 50 Gy, which is more than 30 Gy less than 
when dose is prescribed to the 60% isodose line (Fig. 2). The 
total mean PTV dose is even lower if the dose is prescribed 
to the isocenter. In addition, dose calculation algorithms used 
by treatment-planning systems, such as pencil beam versus 
Monte Carlo calculations, can also cause dose variations of 
up to 15% or more. Therefore, it is very important to make 
sure that the PTV receives adequate dose coverage and that 
an appropriate dose calculation algorithms is used. In addi-
tion, the total PTV mean dose should be considered in the 
comparison of different prescription approaches. Considering 
that optimal local control has been achieved by the historical 
approach of creating a much higher dose in the GTV using 
multiple beams aimed at the isocenter, we should avoid using 
homogenous dose distribution within the target and thus pre-
venting a higher GTV dose when IMRT is used.
SABR plans should be optimized to have high-dose 
regions in the GTV and sharp fall-off outside the PTV. Three-
dimensional conformal radiation therapy or IMRT (including 
volumetric-modulated arc therapy [VMAT]) SABR plans are 
typically used and optimized using 6 to 12 coplanar or non-
coplanar 6-MV photon beams (three-dimensional conformal 
radiation therapy or IMRT) or 1- to 3-arc VMAT. The SABR 
dose should be prescribed to the PTV between the 60% and 
90% (typically 80–85%) isodose lines, using appropriate cal-
culation algorithms with heterogeneity correction. IMRT and 
VMAT plans should be designed with optimization goals to 
achieve these results. Specifically, the GTV should be opti-
mized to a dose between 10% and 30% higher than the pre-
scription isodose line, and a 50% higher dose to the isocenter 
is acceptable (Fig. 2). The fall-off outside the PTV should be 
optimized such that a dose of less than 50% of the prescription 
isodose is beyond 2 cm of the PTV. Both of these requirements 
should be evaluated on a patient-by-patient basis. The fall-
off recommendation in particular should be sacrificed when 
needed to achieve critical structure sparing (i.e., allowing the 
dose to fall-off less sharply in one direction so that it can fall-
off more quickly closer to a critical structure). The fall-off 
requirement should also be balanced against sparing of the 
contralateral lung. The total mean PTV dose should be consid-
ered to evaluate the actual dose received by PTV; the greater 
than or equal to 20% prescribed dose for the total PTV mean 
dose seems appropriate, although more data are needed to val-
idate this. Dose-volume constraints for nearby critical struc-
tures based on the published literature should be considered, 
and compromise to PTV coverage may be needed to maintain 
the normal-structure constraints. However, the internal GTV 
(iGTV) plus a margin of 5 mm (PiGTV) must receive at least 
95% of the prescribed dose, at least 95% of the PiGTV must 
be covered by at least the prescribed dose, and 100% of the 
iGTV must be covered by at least the prescribed dose while 
respecting the dose-volume constraints for normal tissues. If 
FIGURE 2.  Treatment plans and 
dose-volume histograms illustrate 
differences in doses to the mean PTV 
when doses are prescribed (Rx) to 
the 60%, 80%, and 100% isodose 
lines. PTV, planning target volume.
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these requirements cannot be met, then regimens that involve 
additional fractions should be considered.
Use of SABR beam angle/weighting optimization with 
tight aperture margins is crucial to create a sharp dose gra-
dient that provides adequate target coverage while avoiding 
overdosing critical structures (Fig. 3). To further reduce long-
term toxicity, we must continue to seek strategies for minimiz-
ing late toxicity by keeping critical structure dose as low as 
possible while simultaneously not compromising PTV cover-
age. SABR beam angles should be optimized based on bal-
ancing target coverage and sparing certain critical structures 
to improve the therapeutic ratio and efficacy (Fig. 3). Daily 
CT-on-rail or a cone-beam CT scans or implemented fiducial 
tracking should be used during each radiotherapy fraction to 
verify and adjust coverage of the target volume and to spare 
critical structures as needed.
PROTON-BASED STEREOTACTIC 
RADIOTHERAPY
The application of protons for delivering SABR to early 
stage NSCLC has emerged as a tool that may reduce the risk 
of normal tissue toxicity in patients with complicated presen-
tations.30 The advantage of proton therapy lies in its ability to 
minimize dose to normal tissues distal to the tumor. Thus, pro-
ton therapy may offer clinical benefits for patients with limited 
pulmonary reserve, tumors in close geometric proximity to 
critical normal structures, or those who have received prior 
thoracic radiation. In such cases, reducing radiation damage to 
normal tissues is an absolute priority. This may translate into 
clinical benefit and via reducing the risk of clinical toxicity in 
some patients.
Loma Linda University has the longest-term experience 
with proton SABR. In one study by Bush et al.31 involving 
treatment escalation from 51 Gy to 70 Gy in 10 fractions, 
local control and survival were both improved with the 
higher doses. No patient experienced radiation pneumonitis, 
suggesting that the dose could be increased further, possibly 
improving outcomes. However, uncertainties of motion and 
proton range remain. Currently, larger PTV margin might be 
needed for proton-based SABR. Obviously, proton cannot 
spare critical structures if these structures are within PTV. A 
phase II randomized clinical trial comparing proton versus 
photon-based SABR for centrally located or recurrent lung 
parenchymal early stage NSCLC is currently ongoing (http://
clinicaltrials.gov/show/NCT01511081). As the availability of 
proton therapy expands and the experience with this form of 
therapy matures, improvements will continue to be made in 
its implementation. Emerging techniques such as intensity-
modulated proton therapy and on-board volumetric image 
guidance within proton facilities will continue to reduce 
uncertainties and refine dose conformality.32
EVALUATING LOCAL AND REGIONAL LYMPH 
NODE CONTROL
The use of CT or positron emission tomography (PET)/
CT for follow-up after SABR remains controversial. Indeed, 
SABR induces significant consolidation of lung parenchyma 
and has been associated with residual activity on PET, which 
may contribute to differences in reported local control rates.33 
This difficulty with interpreting follow-up images could be 
worse for central lesions, because the proximity to the bron-
chial tree may increase the incidence of atelectasis after 
SABR. Some evidence exists to suggest that certain morpho-
logic changes on CT after SABR can predict local recurrence, 
although further validation is needed.34,35 Also, high standard-
ized uptake values (SUVs greater than five) on PET more than 
6 months after SABR should raise suspicion for local recur-
rence, and close follow-up is indicated.33 If the SUV remains 
high on sequential images, biopsy should be considered to 
confirm local recurrence.
The rate of lymph node recurrence after SABR is 
between 5% and 10%,36 which is comparable to recurrence 
FIGURE 3.  Beam-angle-optimized SABR plans for 
delivering 50 Gy in four fractions while keeping 
target coverage and avoiding overdoses to nearby 
critical structures for tumors in four locations: near 
the brachial plexus (A); near the major vessels (B); 
near the bronchial tree, esophagus and spinal cord 
(C); and near the esophagus and heart (D). Color 
wash dose distributions are shown with correspond-
ing scales. The gray area inside the high-dose region 
indicates where the dose was higher than the scale 
maximum (6238 cGy). BP, brachial plexus; PV, 
pulmonary vessel; BT, bronchial tree; E, esophagus; 
SC, spinal cord; A, aorta; H, heart; GTV, gross tumor 
volume; SABR, stereotactic ablative radiotherapy.
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rates after surgical resection. Generally, central lesions are 
considered to have a higher probability of regional lymph node 
recurrence compared with peripheral lesions.37 The modern 
staging workup, including PET/CT, endobronchial ultraso-
nography, and mediastinoscopy has helped to detect disease 
in lymph nodes, and hence stage the disease, more accurately. 
Moreover, a recent case-matched analysis indicated that an 
incidental dose of greater than 20 Gy to hilar lymph nodes, 
which is likely in the treatment of central lesions, may help 
to prevent lymph node recurrence after SABR.37 However, at 
this moment, there is no data to support treating lymph nodes 
prophylactically in central lesions.
IMMUNOTHERAPY AND  
SABR: I-SABR
Although SABR can produce local control rates in 
excess of 90%, distant metastasis remains a dominant pattern 
of failure, occurring in 10% to 20% of cases.36 Like regional 
lymph node recurrence, the risk of distant metastasis from 
central lesions could be higher than from peripheral lesions. 
In addition, due to the concern of the toxicity of proximal 
critical structures, the target coverage of some central lesions 
might have to be compromised. Further improvements in the 
therapeutic ratio of SABR for central lesions require novel 
approaches to overcome the compromised target coverage 
and/or distant metastases. Although radiation therapy is gener-
ally used to treat localized targets within PTV, it is also known 
to have systemic effects through its ability to recruit biological 
effectors outside the treatment field.38 High doses of radiother-
apy, such as those used in SABR, have been shown to induce 
objective tumor regression outside the irradiated field; this 
phenomenon is called the abscopal effect.39,40 SABR results 
in local tumor sterilization with the release of tumor cell frag-
ments that contain molecules that may be immunogenic, and 
thus radiation can be considered to function as an in situ vac-
cine. Emerging evidence suggests that lung tumors can evoke 
specific antitumoral immune responses in cancer and that 
manipulating the immune system may be a valid therapeu-
tic approach. The immune response to these tumor antigens 
is regulated by cells and molecules with the ability to inhibit 
immune responses via immunologic response checkpoint 
pathways. Antibodies against participants in the checkpoint 
signaling pathways, such as PD1 and CTLA-4, and tumor cell 
vaccines seem to be attractive approaches for inducing antitu-
mor effects and improving disease-free survival in NSCLC.41–
45 Immunotherapy with anti-CTLA-4 antibodies such as 
ipilumumab can release the immune-response inhibition and 
work synergistically with a SABR-induced immune response. 
Indeed, the combination of SABR and ipilumumab has led 
to complete clinical response, including response of multiple 
distant metastases in melanoma.46 The combination of SABR 
and IL-2 immunotherapy has also achieved surprisingly high 
clinical response rates (greater than 50% complete response 
on PET) in melanoma and renal cell carcinoma.47 SABR-
induced immune response was considered the main mecha-
nism for these abscopal effects. Furthermore, preliminary 
clinical findings suggest that adding immunotherapy to SABR 
may be effective against advanced refractory lung cancer.48 By 
triggering an immune response to wipe out residual disease, 
combining immunotherapy with SABR has the potential to 
significantly improve clinical outcome by reducing regional 
and distant metastasis, and may allow us to deliver less than 
100 Gy to the some of the target while maintaining greater 
than 95% local control that may be needed for some of the 
central lesions that compromised target coverage has to be 
considered due to toxicity.
SUMMARY
SABR is a double-edged sword that can kill cancer 
cells but can also damage surrounding critical structures; this 
is a particular concern for lesions in the central thorax. Well-
designed SABR requires a sharp dose gradient from ablative 
dose to tolerable dose and balance target coverage and criti-
cal normal tissue dose-volume constraints. Appropriate case 
selection and SABR dose regimens based on target loca-
tion are crucial to reduce toxicity. Critical structures such 
as the esophagus, bronchial tree, spinal cord, major vessel, 
heart, brachial plexus, and trachea should not receive an 
ablative dose. Involved hilar lymph nodes and mediastinal 
lymph nodes should not be treated with SABR because of 
their proximity to these critical structures. The dose-volume 
constraints proposed here are meant as a guide to help clini-
cians to decide where the limits should be for achieving this 
balance between targeting the tumor and protecting nearby 
critical normal tissue structures. Prospective clinical trials to 
validate these data are needed and should be strongly encour-
aged. The dose to critical structures should be kept as low as 
possible. Because distant metastasis remains a dominant pat-
tern of failure in patients after SABR, the identification of a 
molecular marker to predict distant metastasis would help 
clinicians to identify which patients would need adjuvant 
systemic treatment. Novel forms of immunotherapy may 
also help to prevent or eliminate tumor recurrence, metasta-
sis, and secondary lung cancer. Although the location of the 
tumor to be treated with SABR is important for achieving 
an optimal therapeutic ratio, a more important factor is how 
much dose is delivered to the target versus nearby critical 
normal tissues. A central location in and of itself is not a 
“no fly zone” for SABR; the key is to know and maintain 
the dose-volume constraints for each critical structure and 
to optimize SABR to avoid dangerous side effects. Ablative 
doses are fatal to tumors; they may well also be fatal to criti-
cal normal tissues. Therefore, SABR should be designed 
carefully to kill the tumor but respect the critical normal tis-
sues. If this goal cannot be met, a different treatment strategy 
is needed.
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